Nabihah Tayob

Apr 15, 2024 | nature.com | Qingchun Jin |Ann H. Partridge |Brittany L. Bychkovsky |Giuseppe Curigliano |Nabihah Tayob |Sara M. Tolaney

AbstractFollowing the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated.

Mar 19, 2024 | nature.com | Ann H. Partridge |Beth Overmoyer |Nabihah Tayob |Sara M. Tolaney |Qingchun Jin |Alyssa Pereslete | +1 more

AbstractThe landscape of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistance is still being elucidated and the optimal subsequent therapy to overcome resistance remains uncertain. Here we present the final results of a phase Ib/IIa, open-label trial (NCT02871791) of exemestane plus everolimus and palbociclib for CDK4/6i-resistant metastatic breast cancer.

Jan 1, 2024 | nature.com | Jennifer L. Guerriero |Ziming Du |Siyang Ren |Nabihah Tayob |Shaolin Mei |Sara M. Tolaney | +1 more

AbstractEmerging data suggests that HER2 intratumoral heterogeneity (ITH) is associated with therapy resistance, highlighting the need for new strategies to assess HER2 ITH. A promising approach is leveraging multiplexed tissue analysis techniques such as cyclic immunofluorescence (CyCIF), which enable visualization and quantification of 10–60 antigens at single-cell resolution from individual tissue sections.